Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company's preclinical stage product candidate includes KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate conjugate to treat neovascular retinal diseases with an inflammatory component. Its early research pipeline includes KSI-601, a triplet inhibitor for the treatment of multifactorial retinal diseases, such as dry AMD and the neurodegenerative aspects of glaucoma. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is based in Palo Alto, California.
IPO Year: 2018
Exchange: NASDAQ
Website: kodiak.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2024 | $20.00 | Hold → Buy | Jefferies |
| 9/5/2024 | $3.00 | Neutral | H.C. Wainwright |
| 12/11/2023 | $2.00 | Sell | Goldman |
| 11/17/2023 | $7.00 → $12.00 | Equal Weight → Overweight | CapitalOne |
| 7/27/2023 | $15.00 → $4.00 | Buy → Neutral | UBS |
| 7/25/2023 | Buy → Neutral | Chardan Capital Markets | |
| 7/25/2023 | Neutral → Underweight | JP Morgan | |
| 7/24/2023 | Buy → Hold | Jefferies | |
| 7/24/2023 | $7.00 | Overweight → Equal Weight | CapitalOne |
| 11/15/2022 | $24.00 | Overweight | CapitalOne |
DEFA14A - Kodiak Sciences Inc. (0001468748) (Filer)
DEF 14A - Kodiak Sciences Inc. (0001468748) (Filer)
S-8 - Kodiak Sciences Inc. (0001468748) (Filer)
10-K - Kodiak Sciences Inc. (0001468748) (Filer)
8-K - Kodiak Sciences Inc. (0001468748) (Filer)
10-Q - Kodiak Sciences Inc. (0001468748) (Filer)
8-K - Kodiak Sciences Inc. (0001468748) (Filer)
10-Q - Kodiak Sciences Inc. (0001468748) (Filer)
8-K - Kodiak Sciences Inc. (0001468748) (Filer)
8-K - Kodiak Sciences Inc. (0001468748) (Filer)
Jefferies upgraded Kodiak Sciences from Hold to Buy and set a new price target of $20.00
H.C. Wainwright initiated coverage of Kodiak Sciences with a rating of Neutral and set a new price target of $3.00
Goldman resumed coverage of Kodiak Sciences with a rating of Sell and set a new price target of $2.00
CapitalOne upgraded Kodiak Sciences from Equal Weight to Overweight and set a new price target of $12.00 from $7.00 previously
UBS downgraded Kodiak Sciences from Buy to Neutral and set a new price target of $4.00 from $15.00 previously
Chardan Capital Markets downgraded Kodiak Sciences from Buy to Neutral
JP Morgan downgraded Kodiak Sciences from Neutral to Underweight
Jefferies downgraded Kodiak Sciences from Buy to Hold
CapitalOne downgraded Kodiak Sciences from Overweight to Equal Weight and set a new price target of $7.00
CapitalOne initiated coverage of Kodiak Sciences with a rating of Overweight and set a new price target of $24.00
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
PALO ALTO, Calif., Sept. 17, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that it will host an Investor R&D Day with financial analysts and institutional investors on Monday, September 23, 2024, in New York City from 10:30 am ET to 12:30 pm ET. The event will feature presentations and roundtable discussions on Kodiak's science of durability, science of the enhanced formulation, timeline and other updates for the Company's active clinical pipeline, and the Company's expanding Antibody Biopolymer Conjugate Dr
SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Julie Iwashita as the company’s Vice President of Clinical Operations. Ms. Iwashita brings more than 30 years of experience guiding global neurology and other clinical development programs through the U.S. Food and Drug Administration (FDA) and other global health authorities. “I am delighted to welcome Julie to Pipeline Therapeutics to spearhead our clinical development efforts,” said Carmine Stengone, President & CEO of Pipeline Therapeutics. “Julie’s extensive
PALO ALTO, Calif., March 26, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that it will report fourth quarter and full-year 2023 financial results on Thursday, March 28, 2024. Management will host a conference call and live webcast to discuss recent business highlights and provide a corporate update at 4:30 p.m. Eastern Time on March 28, 2024. To access the webcast, please register at https://edge.media-server.com/mmc/p/q4jdxku4/. A live audio webcast of the event will be available on the "Events and Presentatio
PALO ALTO, Calif., Feb. 23, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3 clinical trial evaluating the efficacy, durability and safety of KSI-301, a novel antibody biopolymer conjugate, in treatment-naïve subjects with neovascular (wet) age-related macular degeneration. The trial randomized 559 participants, approximately 80% of whom were enrolled in the United States. The study had two treatment arms: KSI-301 5mg on a flexible long-interval regimen and aflibercept 2mg on a fixed short-interval regimen. In the study, three monthly loading doses were administered to all subje
PALO ALTO, Calif., May 1, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that seven scientific presentations on its research programs will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting, being held from May 4-8 in Salt Lake City, Utah. "We are pleased to share new data from Kodiak's research and development efforts at this year's ARVO meeting. This body of work further highlights the power and versatility of Kodiak's ABC® (Antibody Biopolymer Conjugate) platform for
PALO ALTO, Calif., March 27, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "In September of 2024 we hosted an Investor R&D Day in New York," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The Investor R&D Day webcast and presentation featured scientific, clinical and commercial perspectives and included key retina opinion leaders. It was an important snapshot of where we stood at that time, and where we were going – we called it Kodiak 2.0. Six months later, we are well on track." "It is remarkable that after twenty years of anti-V
Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026.GLOW2 study design mirrors GLOW1 study, which met primary endpoint and all key secondary endpoints with high statistical significancePALO ALTO, Calif., March 10, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabetic retinopathy ("DR"). "We randomized more than 250 patients into our GLOW2 Phase 3 study, exceeding our enrollment target," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak. "With its 48-week duration of treatment, all patients are expected to com
PALO ALTO, Calif., Feb. 4, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that senior management will present the Company's pipeline program exploring the treatment of glaucoma at the Glaucoma 360 New Horizons Forum 2025 on Friday, February 7, 2025, in San Francisco, CA. Glaucoma is the leading cause of irreversible blindness, affecting approximately 76 million people worldwide. This optic neuropathy progressively damages the optic nerve, leading to partial or total vision loss. Emerging research identifies n
PALO ALTO, Calif., Jan. 7, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that Victor Perlroth, M.D., Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025, at 3:00 p.m. Pacific Time. A live webcast of the presentation will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the event. About Kodiak Sciences In
CAMBRIDGE, Mass., Dec. 9, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, today announced a collaboration with Kodiak Sciences Inc. (NASDAQ:KOD). This partnership aims to advance the discovery of novel multi-target antibodies to treat ophthalmic diseases, leveraging Nona's proprietary Harbour Mice® fully human antibody platform. The Harbour Mice® platform generates fully human monoclonal antibodies in both the two h
PALO ALTO, Calif., Nov. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The Investor R&D Day webcast and presentation provide a comprehensive and up-to-date overview of where we stand today and where we are going – this is what I call 'Kodiak 2.0'. The video webcast includes scientific, clinical and commercial perspectives from key retina opinion leaders Dr. David Brown and Dr. Charles Wykoff. We encourage you to study these materials which are
PALO ALTO, Calif., Nov. 11, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences. Members of the management team will also be available for one-on-one meetings. Jefferies London Healthcare Conference, November 21, 2024, 9:00 AM GMT (1:00 AM PT), London, UK7th Annual Evercore ISI HealthCONx Conference, December 3, 2024, 2:35 PM ET (11:35 AM PT), Coral Gables, FloridaA live webcast of both presentations will be available on the "Events and Pr
PALO ALTO, Calif., Oct. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today its participation in a presentation and panel at Innovate Retina 2024 on October 17, 2024, in Chicago, Illinois. Presentation and Panel details are below: Presentation Title: Update on Antibody Biopolymer Conjugates: Optimizing Immediacy and DurabilityTime: 3:30 PM CTPresenter: Mark Barakat, M.D., FASRS, Clinical Assistant Professor of Ophthalmology, University of Arizona College of Medicine – Phoenix; Founder and Director of Research,
NEW YORK, Sept. 23, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), will host its Investor R&D Day today in New York. The event is from 10:30 am ET to 12:30 pm ET and can be accessed virtually at https://edge.media-server.com/mmc/p/2ff5vrm7. A link to the live webcast, replay and presentation slides of the event will be available on the "Events and Presentations" section of Kodiak's Investors & Media website at http://ir.kodiak.com/. A replay of the webcast will be available for a limited time following the event. The event will feature speakers from members of the Kodiak leadership team and the following leading retina specialist key opinion leaders (KOLs): David Brown, MD, Clinica
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13G - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13D/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13D/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)